Eyewire Today http://eyewiretoday.com/ Eyewire Today en-us Sun, 4 Dec 2016 02:49:53 GMT Sun, 4 Dec 2016 02:49:53 GMT EyewireToday.com Genetic Mutation Tied to Risk of Early Parkinson’s Disease http://eyewiretoday.com/view.asp?url=genetic-mutation-tied-to-risk-of-early-parkinsons-disease Aging appears to alter how genetic factors contribute to the development of Parkinson’s disease, according to new research that has identified a gene that may increase risk of early onset Parkinson’s disease. Investigating the differences... Tue, 29 Nov 2016 04:00:00 GMT Saliva Test May Detect Alzheimer’s Disease http://eyewiretoday.com/view.asp?url=saliva-test-may-detect-alzheimers-disease A new saliva test developed by Aurin Bitech could serve as a diagnostic marker for Alzheimer’s disease, according to new findings published the Journal of Alzheimers Disease. The test is based on measuring the concentration of amyloid beta prot... Tue, 22 Nov 2016 04:00:00 GMT AMA Takes Policy Steps to Encourage Further CTE Research http://eyewiretoday.com/view.asp?url=ama-takes-policy-steps-to-encourage-further-cte-research The American Medical Association (AMA) has recently adopted new policies urging further research into the detection, causes, and prevention of head injuries. In particular, the policies encourage efforts to develop diagnostic tools as well as to unde... Wed, 16 Nov 2016 04:00:00 GMT Phase 1 Data Show Rapid Absorption of Intranasal Midazolam in Pediatric Patients with Epilepsy http://eyewiretoday.com/view.asp?url=phase-i-data-show-rapid-absorption-of-intranasal-midazolam-in-pediatric-patients-with-epilepsy New Phase 1 data show that intranasal midazolam spray (USL261, Upsher-Smith) in pediatric participants with epilepsy is rapidly absorbed and with no dose-dependent no differences in maximum plasma concentration. USL261 is being developed for the resc... Fri, 28 Oct 2016 04:00:00 GMT Tramiprosate Shows Gene-Dose Effect in Alzheimer’s Patients with APOE4 http://eyewiretoday.com/view.asp?url=tramiprosate-shows-gene-dose-effect-in-alzheimers-patients-with-apoe4 New phase 3 findings suggest that the investigational amyloid-targeted agent tramiprosate may particularly effective for patients with ε4 alleles of apolipoprotein E (APOE4), a genetic risk factor in mild to moderate Alzheimer’s disease... Tue, 25 Oct 2016 04:00:00 GMT Oral Bacteria Linked to Migraine http://eyewiretoday.com/view.asp?url=oral-bacteria-linked-to-migraine Oral bacteria that convert nitrates into nitric oxide in the blood may be the key to understanding the cause of migraines, according to newly published findings. In a study published in mSystems from the American Society for Microbiology, migraine su... Mon, 24 Oct 2016 04:00:00 GMT Parkinson’s Disease Therapeutic Conference to Spotlight New Research and Potential Therapeutic Targets http://eyewiretoday.com/view.asp?url=parkinsons-disease-therapeutic-conference-to-spotlight-new-research-and-potential-therapeutic-targets The Michael J. Fox Foundation’s 10th annual Parkinson’s Disease Therapeutic Conference, set to take place on October 24 in New York City, will bring together experts and specialists in research and business development to discuss the late... Wed, 12 Oct 2016 04:00:00 GMT Skin Disorder Tied to Increased Risk of Alzheimer’s Disease http://eyewiretoday.com/view.asp?url=20160502-skin_disorder_tied_to_increased_risk_of_alzheimers_disease A new study has uncovered an increased risk of dementiain particular Alzheimers diseasein patients with rosacea, a chronic inflammatory skin disease. The risk may be highest in older patients and in patients where rosacea was diagnosed by a hospital ... Mon, 2 May 2016 14:59:00 GMT Alnylam Releases Data from Ongoing Phase 2 Open-Label Extension Study of Investigation Agent for Hereditary ATTR Amyloidosis with Polyneuropathy http://eyewiretoday.com/view.asp?url=20160420-alnylam_releases_data_from_ongoing_phase_2_open-label_extension_study_of_investigation_agent_for_hereditary_attr_amyloidosis_with_polyneuropathy Alnylam Pharmaceuticals, Inc. unveiled complete 18-month data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of hereditary ATTR amyloidosis... Wed, 20 Apr 2016 18:02:00 GMT AAN Meeting: More than One Million Annual ER Visits Epilepsy-Related http://eyewiretoday.com/view.asp?url=20160419-aan_meeting_more_than_one_million_annual_er_visits_epilepsy-related New data presented at the at the Annual Meeting of the American Academy of Neurology (AAN) in Vancouver suggest that there are substantial unmet needs related to seizure emergency management and coordination of care for patients with epilepsy. A coho... Tue, 19 Apr 2016 12:39:00 GMT Survey Findings Suggest Low Awareness for ULS http://eyewiretoday.com/view.asp?url=20160412-survey_findings_suggest_low_awareness_for_uls Findings from a new survey revealed that awareness of the signs and symptoms of adult Upper Limb Spasticity (ULS) is low among Americans. The survey was conducted by Harris Poll and commissioned by Merz Neurosciences. The survey was conducted online ... Tue, 12 Apr 2016 19:18:00 GMT Data for Investigational Levodopa for Subcutaneous Infusion to be Presented at AAN Annual Meeting http://eyewiretoday.com/view.asp?url=20160406-data_for_investigational_levodopa_for_subcutaneous_infusion_to_be_presented_at_aan_annual_meeting Recent data for the investigational levodopa/carbidopa agent ND0612 will be presented at the American Academy of Neurology (AAN) annual meeting in Vancouver, BC. According to NeuroDerm, the AAN has identified the companys submission, Stable levodopa ... Wed, 6 Apr 2016 13:39:00 GMT Migraine Prevention Drug Shows Potential in Phase 2b Trial http://eyewiretoday.com/view.asp?url=20160329-migraine_prevention_drug_shows_potential_in_phase_2b_trial An investigational agent from Alder BioPharmaceuticals has shown promise for migraine prevention, according to new clinical trial data released by the company. In a Phase 2b study, ALD403, a monoclonal antibody that targets calcitonin gene-related pe... Tue, 29 Mar 2016 16:37:00 GMT Human Stem Cells Used to Target Huntington’s Disease http://eyewiretoday.com/view.asp?url=20160317-human_stem_cells_used_to_target_huntingtons_disease A new approach using stem cells may yield diminished neuron loss, reduced symptoms, and extended life in Huntingtons disease, new research suggests. A team of UC Davis investigators has identified a way to use human mesenchymal stem cells (MSCs) to d... Thu, 17 Mar 2016 15:57:00 GMT Patient Enrollment Begins on Largest Brain Amyloid Scanning Study http://eyewiretoday.com/view.asp?url=20160302-patient_enrollment_begins_on_largest_brain_amyloid_scanning_study Participating dementia specialists may now enroll patients to participate in the Imaging DementiaEvidence for Amyloid Scanning (IDEAS) Study at IDEAS-Study.org. The IDEAS Study will follow more than 18,000 Medicare beneficiaries to determine the clin... Wed, 2 Mar 2016 16:27:00 GMT Research Consortium Identifies Key Piece in Parkinson's Disease Pathology http://eyewiretoday.com/view.asp?url=20160129-research_consortium_identifies_key_piece_in_parkinsons_disease_pathology An international public-private research consortium has identified and validated a cellular role of a primary Parkinson's disease drug target: the LRRK2 kinase. Published in the open-access eLife journal (http://dx.doi.org/10.7554/eLife.12813), the f... Fri, 29 Jan 2016 18:27:00 GMT High Levels of Urate in Blood Associated with Lower Risk of Parkinson’s Disease http://eyewiretoday.com/view.asp?url=20160114-high_levels_of_urate_in_blood_associated_with_lower_risk_of_parkinsons_disease Men who have high levels of urate in their blood may be less likely to develop Parkinsons disease, according to a study published in Neurology (January 13). Urate is formed when purines are broken down in the body. The study evaluated 90,214 particip... Thu, 14 Jan 2016 18:45:00 GMT Blocking Inflammation Shown to Slow Alzheimer’s Development http://eyewiretoday.com/view.asp?url=20160111-blocking_inflammation_shown_to_slow_alzheimers_development Blocking inflammation in the brain may slow the progression of Alzheimers disease (AD), according to a new study published in Brain (January 6). To understand migroglial proliferation in AD and the potential efficacy of inhibiting the colony-stimulat... Mon, 11 Jan 2016 19:38:00 GMT Estriol Combined with Glatiramer Acetate Found Effective for Women with Relapsing-Remitting MS http://eyewiretoday.com/view.asp?url=20160107-estriol_combined_with_glatiramer_acetate_found_effective_for_women_with_relapsing-remitting_ms Estriol plus glatiramer acetate may reduce relapse rates in women with relapsing-remitting multiple sclerosis (MS), new findings indicate. Noting that preclinical studies have shown that estriol treatment is anti-inflammatory and neuroprotective, the... Thu, 7 Jan 2016 15:47:00 GMT Hepatitis C Associated with Increased Risk of Parkinson’s Disease http://eyewiretoday.com/view.asp?url=20160105-hepatitis_c_associated_with_increased_risk_of_parkinsons_disease The hepatitis C virus may be associated with an increased risk of developing Parkinsons disease, according to new data published in Neurology. In the Taiwanese study, investigators placed participants with hepatitis into three groupsthose infected wi... Tue, 5 Jan 2016 19:05:00 GMT NeuroDerm Starts Patient Enrollment in Phase II Trial of ND0612H for Advanced Parkinson’s Disease http://eyewiretoday.com/view.asp?url=20151230-neuroderm_starts_patient_enrollment_in_phase_ii_trial_of_nd0612h_for_advanced_parkinsons_disease NeuroDerm Ltd. announced the start of patient enrollment in a first efficacy trial of ND0612H, the company's continuously administered subcutaneous levodopa/carbidopa solution. This treatment is intended to be an alternative to current treatments for... Wed, 30 Dec 2015 15:07:00 GMT Study to Test Effectiveness of App to Track Concussions http://eyewiretoday.com/view.asp?url=20151215-study_to_test_effectiveness_of_app_to_track_concussions Researchers at NYU Langone Medical Center will begin testing whether a new free mobile app for iPhone and Apple Watch can help those with concussions better track their symptoms during the critical six weeks following their diagnosis. The ResearchKit... Tue, 15 Dec 2015 18:21:00 GMT Ischemic Stroke Risk in Young Adults More Pronounced in African Americans http://eyewiretoday.com/view.asp?url=20151209-ischemic_stroke_risk_in_young_adults_more_pronounced_in_african_americans New findings suggest pronounced ethnic differences in ischemic stroke subtypes in young adults. In a new study published in BMC Neurology (October 29, 2015), authors conducted a population-based study controlling for age and sex, finding that African... Wed, 9 Dec 2015 16:48:00 GMT Adverse Events and Use of Healthcare Resources More Prevalent Among Those Not Using Rescue Medications for Seizure Clusters http://eyewiretoday.com/view.asp?url=20151208-adverse_events_and_use_of_healthcare_resources_more_prevalent_among_those_not_using_rescue_medications_for_seizure_clusters New data presented at the Annual Meeting of American Epilepsy Society Annual Meeting found there were more adverse outcomes and greater use of healthcare resources among those who did not always use a rescue medication to treat seizure clusters, comp... Tue, 8 Dec 2015 16:43:00 GMT Neural Stem Cells Found to Promote Remyelination http://eyewiretoday.com/view.asp?url=20151123-neural_stem_cells_found_to_promote_remyelination Endogenous neural stem cells might offer a new therapeutic avenue for the treatment of demyelinating disorders such as MS, according to a new study published in Nature (October 15, 2015). Specifically, the authors looked at a subset of adult neural s... Mon, 23 Nov 2015 17:33:00 GMT